Literature DB >> 29273600

Deficiency of Natriuretic Peptide Receptor 2 Promotes Bicuspid Aortic Valves, Aortic Valve Disease, Left Ventricular Dysfunction, and Ascending Aortic Dilatations in Mice.

Mark C Blaser1, Kuiru Wei1, Rachel L E Adams1, Yu-Qing Zhou1, Laura-Lee Caruso1, Zahra Mirzaei1, Alan Y-L Lam1, Richard K K Tam1, Hangjun Zhang1, Scott P Heximer1, R Mark Henkelman1, Craig A Simmons2.   

Abstract

RATIONALE: Aortic valve disease is a cell-mediated process without effective pharmacotherapy. CNP (C-type natriuretic peptide) inhibits myofibrogenesis and osteogenesis of cultured valve interstitial cells and is downregulated in stenotic aortic valves. However, it is unknown whether CNP signaling regulates aortic valve health in vivo.
OBJECTIVE: The aim of this study is to determine whether a deficient CNP signaling axis in mice causes accelerated progression of aortic valve disease. METHODS AND
RESULTS: In cultured porcine valve interstitial cells, CNP inhibited pathological differentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2) and not the G-protein-coupled clearance receptor NPR3 (natriuretic peptide receptor 3). We used Npr2+/- and Npr2+/-;Ldlr-/- mice and wild-type littermate controls to examine the valvular effects of deficient CNP/NPR2 signaling in vivo, in the context of both moderate and advanced aortic valve disease. Myofibrogenesis in cultured Npr2+/- fibroblasts was insensitive to CNP treatment, whereas aged Npr2+/- and Npr2+/-;Ldlr-/- mice developed cardiac dysfunction and ventricular fibrosis. Aortic valve function was significantly impaired in Npr2+/- and Npr2+/-;Ldlr-/- mice versus wild-type littermates, with increased valve thickening, myofibrogenesis, osteogenesis, proteoglycan synthesis, collagen accumulation, and calcification. 9.4% of mice heterozygous for Npr2 had congenital bicuspid aortic valves, with worse aortic valve function, fibrosis, and calcification than those Npr2+/- with typical tricuspid aortic valves or all wild-type littermate controls. Moreover, cGK (cGMP-dependent protein kinase) activity was downregulated in Npr2+/- valves, and CNP triggered synthesis of cGMP and activation of cGK1 (cGMP-dependent protein kinase 1) in cultured porcine valve interstitial cells. Finally, aged Npr2+/-;Ldlr-/- mice developed dilatation of the ascending aortic, with greater aneurysmal progression in Npr2+/- mice with bicuspid aortic valves than those with tricuspid valves.
CONCLUSIONS: Our data establish CNP/NPR2 signaling as a novel regulator of aortic valve development and disease and elucidate the therapeutic potential of targeting this pathway to arrest disease progression.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  aortic aneurysm; aortic valve; aortic valve stenosis; natriuretic peptide, C-type; ventricular dysfunction, left

Mesh:

Substances:

Year:  2017        PMID: 29273600     DOI: 10.1161/CIRCRESAHA.117.311194

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  18 in total

Review 1.  Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch.

Authors:  Jianghui Meng; Weiwei Chen; Jiafu Wang
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

2.  Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.

Authors:  Simon Kraler; Mark C Blaser; Elena Aikawa; Giovanni G Camici; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2022-02-12       Impact factor: 29.983

Review 3.  Genetic and Developmental Contributors to Aortic Stenosis.

Authors:  Punashi Dutta; Jeanne F James; Hail Kazik; Joy Lincoln
Journal:  Circ Res       Date:  2021-04-29       Impact factor: 17.367

Review 4.  Multi-Omics Approaches to Define Calcific Aortic Valve Disease Pathogenesis.

Authors:  Mark C Blaser; Simon Kraler; Thomas F Lüscher; Elena Aikawa
Journal:  Circ Res       Date:  2021-04-29       Impact factor: 17.367

5.  De novo c.2455C>T mutation of NPR2 gene in a fetus with shortened long bones and a ventricular septal defect conceived by a mother with a fragile site at 16q22.1 and a father with a rare heterochromatic variant of chromosome 4 from Vietnam.

Authors:  Thi Minh Thi Ha; Tran Thao Nguyen Nguyen; Thi Mai Ngan Nguyen; Huu Nguyen Nguyen
Journal:  Mol Genet Genomic Med       Date:  2021-03-13       Impact factor: 2.183

Review 6.  2020 Jeffrey M. Hoeg Award Lecture: Calcifying Extracellular Vesicles as Building Blocks of Microcalcifications in Cardiovascular Disorders.

Authors:  Elena Aikawa; Mark C Blaser
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-29       Impact factor: 8.311

Review 7.  Dissecting Calcific Aortic Valve Disease-The Role, Etiology, and Drivers of Valvular Fibrosis.

Authors:  Petra Büttner; Lukas Feistner; Philipp Lurz; Holger Thiele; Joshua D Hutcheson; Florian Schlotter
Journal:  Front Cardiovasc Med       Date:  2021-05-10

8.  Natriuretic peptide receptor B maintains heart rate and sinoatrial node function via cyclic GMP-mediated signalling.

Authors:  Tristan W Dorey; Martin Mackasey; Hailey J Jansen; Megan D McRae; Loryn J Bohne; Yingjie Liu; Darrell D Belke; Logan Atkinson; Robert A Rose
Journal:  Cardiovasc Res       Date:  2022-06-29       Impact factor: 13.081

9.  Engineering a 3D-Bioprinted Model of Human Heart Valve Disease Using Nanoindentation-Based Biomechanics.

Authors:  Dewy C van der Valk; Casper F T van der Ven; Mark C Blaser; Joshua M Grolman; Pin-Jou Wu; Owen S Fenton; Lang H Lee; Mark W Tibbitt; Jason L Andresen; Jennifer R Wen; Anna H Ha; Fabrizio Buffolo; Alain van Mil; Carlijn V C Bouten; Simon C Body; David J Mooney; Joost P G Sluijter; Masanori Aikawa; Jesper Hjortnaes; Robert Langer; Elena Aikawa
Journal:  Nanomaterials (Basel)       Date:  2018-05-03       Impact factor: 5.076

Review 10.  Comparing the Role of Mechanical Forces in Vascular and Valvular Calcification Progression.

Authors:  Madeleine A Gomel; Romi Lee; K Jane Grande-Allen
Journal:  Front Cardiovasc Med       Date:  2019-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.